

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

“ZOLEDRONIC ACID INJECTION” OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Zoledronic Acid Injection (100ml: 4mg)” (the “**Product**”) developed by CSPC NBP Pharmaceutical Co., Ltd* (石藥集團恩必普藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Zoledronic acid is a farnesyl pyrophosphate synthase inhibitor in osteoclasts, which can inhibit bone resorption by inhibiting osteoclastic activity. It is clinically used in combination with standard anti-tumor drugs to treat bone damage in patients with bone metastases from solid tumors and patients with multiple myeloma. It can also be used to treat hypercalcemia of malignancy (HCM). As a drug for adjuvant therapy, the Product can alleviate the suffering of cancer patients.

The approval of the Product will further enhance the Group’s product portfolio and contribute to the Group’s development in the field of oncology.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 10 January 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Professor WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

** For identification purpose only.*